Recurrence of generalized cutaneous lichen planus after switching from PD-1 to PD-L1 in a patient with pre-existing oral lichen planus: a case report. [PDF]
Zhang Y, Li Y, Guo T.
europepmc +1 more source
Antithrombotic Drug Eruptions in Dermatology Practice: Selection Bias, Clinical Phenotypes, and Diagnostic Approaches. [PDF]
Takada T.
europepmc +1 more source
Penicillin allergy documentation in the UAE: 10-year trends and stewardship implications. [PDF]
Alteneiji A, Al-Shamsi S, Almarzooqi F.
europepmc +1 more source
Levofloxacin-Induced Cutaneous Adverse Reactions: Characteristics and Rational Use Strategies. [PDF]
Tian L, Xu S, Guo H.
europepmc +1 more source
Patch Testing Is Useful in Patients With Lamotrigine‐Induced Cutaneous Adverse Drug Reactions
Contact Dermatitis, EarlyView.
E. Bertazzo +4 more
wiley +1 more source
Allopurinol-Induced Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome: A Case Report and Review of the Published Evidence From India. [PDF]
Shinde A +4 more
europepmc +1 more source
Acute oromucosal and palmar desquamation: a severe cutaneous adverse reaction to amphotericin and metronidazole. [PDF]
Connolly R, Russell S.
europepmc +1 more source
Ropeginterferon‐α2b in mycosis fungoides and Sézary syndrome: Safety and efficacy in 41 patients
Summary Background and objectives Pegylated interferon‐α2a became the off‐label alternative for treating mycosis fungoides/Sézary syndrome (MF/SS) after non‐pegylated interferons were withdrawn. This study aimed to evaluate the safety and efficacy of ropeginterferon‐α2b in MF/SS. Patients and methods We performed a retrospective multicenter analysis at
Stefanie Porkert +15 more
wiley +1 more source
Gefitinib treatment after exfoliative dermatitis induced by sequential aumolertinib and furmonertinib in lung adenocarcinoma: a case report. [PDF]
Xiang W, Hu X, Wei J, Cheng Z, Dong X.
europepmc +1 more source

